Lixte Biotechnology (NASDAQ:LIXT) Shares Up 3.5%

Shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTGet Free Report) were up 3.5% during mid-day trading on Tuesday . The company traded as high as $2.17 and last traded at $2.09. Approximately 1,505 shares were traded during trading, a decline of 87% from the average daily volume of 11,612 shares. The stock had previously closed at $2.02.

Lixte Biotechnology Price Performance

The company has a market capitalization of $4.70 million, a P/E ratio of -0.64 and a beta of -0.37. The firm’s 50-day moving average is $2.15 and its 200-day moving average is $2.46.

Lixte Biotechnology (NASDAQ:LIXTGet Free Report) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.49) earnings per share for the quarter.

Institutional Trading of Lixte Biotechnology

Several hedge funds have recently bought and sold shares of the stock. EP Wealth Advisors LLC bought a new stake in shares of Lixte Biotechnology during the 1st quarter valued at $31,000. Renaissance Technologies LLC bought a new stake in Lixte Biotechnology during the second quarter valued at about $43,000. Finally, Geode Capital Management LLC lifted its position in shares of Lixte Biotechnology by 292.4% in the first quarter. Geode Capital Management LLC now owns 101,209 shares of the company’s stock valued at $84,000 after acquiring an additional 75,415 shares in the last quarter. Institutional investors own 11.85% of the company’s stock.

Lixte Biotechnology Company Profile

(Get Free Report)

Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.

Recommended Stories

Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with's FREE daily email newsletter.